Prescient Therapeutics (ASX:PTX) Net Margin %: 0.00% (As of Dec. 2025)


What is Prescient Therapeutics Net Margin %?

Prescient Therapeutics ASX:PTX -3.33% Net Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Prescient Therapeutics ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Prescient Therapeutics's Net Income for the six months ended in Dec. 2025 was A$-3.99 Mil. Prescient Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Prescient Therapeutics's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Prescient Therapeutics's Net Margin % or its related term are showing as below:


ASX:PTX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Prescient Therapeutics  (ASX:PTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Prescient Therapeutics Net Margin % Related Terms

Prescient Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Net Margin % Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:PTX vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Prescient Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Net Margin % falls into.


Prescient Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Prescient Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.323/0
= %

Prescient Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.987/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Prescient Therapeutics (ASX:PTX) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Prescient Therapeutics and its competitors. According to the industry distribution chart, Prescient Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry.
Is Prescient Therapeutics' Net Margin % too high?
Prescient Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Prescient Therapeutics ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Prescient Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #999999 out of 947 companies for Net Margin %. This places Prescient Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.